Related Experiment Video
Updated: Jun 7, 2026

Semiconductor Sequencing for Preimplantation Genetic Testing for Aneuploidy
Published on: August 25, 2019
GPT-3.5 Turbo and GPT-4 Turbo in Title and Abstract Screening for Systematic Reviews
Takehiko Oami1, Yohei Okada2,3, Taka-Aki Nakada1
1Department of Emergency and Critical Care Medicine, Chiba University Graduate School of Medicine, 1-8-1 Inohana, Chuo, Chiba, 260-8677, Japan, 81 432262372.
Large language models (LLMs) show promise in systematic reviews. GPT-4 Turbo offers higher specificity in citation screening, while GPT-3.5 Turbo is faster.
Area of Science:
- Artificial Intelligence
- Medical Informatics
- Systematic Reviews
Background:
- Systematic reviews require efficient literature screening.
- Large language models (LLMs) are increasingly used in research.
- Comparing different LLM versions for specific tasks is crucial.
Purpose of the Study:
- To compare the performance of GPT-4 Turbo and GPT-3.5 Turbo in citation screening for systematic reviews.
- To evaluate specificity, sensitivity, and processing time of both LLM versions.
Main Methods:
- Citation screening was performed using both GPT-4 Turbo and GPT-3.5 Turbo.
- Performance metrics included specificity, sensitivity, and processing time for a set of studies.
Main Results:
- GPT-4 Turbo demonstrated superior specificity (0.98) compared to GPT-3.5 Turbo (0.51).
- Sensitivity was comparable between GPT-4 Turbo (0.85) and GPT-3.5 Turbo (0.83).
- GPT-3.5 Turbo processed studies faster (0.9 min) than GPT-4 Turbo (1.6 min) for 100 studies.
Conclusions:
- GPT-4 Turbo's higher specificity makes it potentially more suitable for citation screening in systematic reviews.
- LLMs offer significant potential for optimizing literature selection processes.
- Further research into LLM applications in evidence synthesis is warranted.
More Related Videos
09:30Pre-Implantation Genetic Testing for Aneuploidy on a Semiconductor Based Next-Generation Sequencing Platform
Published on: August 17, 2022
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
Related Concept Videos
Clinical Trials: Overview
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase